Tumor Immunoprofiling: HISTALIM Launches HISTOPROFILE
Recent clinical data confirm the importance of patient stratification in the development of cancer immunotherapies. For instance Merck’success with Keytruda (Pembrolizumab, anti PDL-1) in lung cancer demonstrates that the patient screening according to the ligand overexpression of the therapeutic target is a winning strategy in immuno-oncology.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170403005576/en/
Though the pertinence of personalized medicine in oncology cannot be argued, one must also consider that the reactivation of the immune system against tumors engage subtle and complex mechanisms, which can be more efficient when multiple pathways are simultaneously activated. This opinion is commonly shared by many researchers in immuno-oncology who engage clinical trials combining therapies against several targets.
If clinical results confirm the relevance of this approach, it will be necessary to qualify patients on the basis of multiple biomarkers. Given the fact that a biopsy can only be used on a few histological slides, an obvious conclusion arises: it becomes urgent to extract several markers from a single slide.
Positive progress of liquid biopsy and molecular biology could potentially address this issue. But these solutions do not allow to localize the marker, which is sometimes required. To get more precise information on the tumor microenvironment, the protein expression is not enough: associated morphologic information needs to be known.
Nowadays several clinical trials in immuno-oncology rely on multiplex immunohistochemistry to use a sufficient number of markers despite the scarcity of biological material. It can be anticipated that the routine histopathologic diagnostic will integrate multiplex analysis of markers so that pathologist can try this new challenge: characterize tumor immune profile from a single biopsy.
Cultural and technological barriers will have to be removed in order to let histopathology progress as fast as the innovations in immuno-oncology. For instance fluorescence revelation is not commonly used by the pathologists. Complex multiplex IHC staining require slide scanners compatible with multispectral imaging, which is not widely spread. Then the volume of data processed from multiplex staining will require to use image analysis solutions able to facilitate the pathologist’s diagnostic. This is a new paradigm for histopathology which is evolving toward a more subtle science than it was already, being source of “rich-data” for the treatment of patients.
This new generation histopathology, led by “augmented pathologists” and able to define the tumor immune profile from one single biopsy, is developed by HISTALIM under the brand named HISTOPROFILE.
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Ved at skrive dig op her, vil du modtage pressemeddelelser på mail når de udsendes. Indtast din mail og følg instruktionerne. Det er ligeså let at melde sig fra igen.
Flere pressemeddelelser fra Business Wire
NY-IFF18.10.2017 22:18 | pressemeddelelse
IFF Launches Re-Imagine…™ Programs to Tap Unmet Consumer Opportunities, Speed Innovation
SPARKOL18.10.2017 15:26 | pressemeddelelse
Sparkol Launches VideoScribe 3
PIRAEUS-BANK18.10.2017 15:08 | pressemeddelelse
Piraeus Bank: Agreement for the Sale of Serbian Operations
NY-INVISION18.10.2017 15:03 | pressemeddelelse
Introducing InVision Studio, The World’s Most Powerful Screen Design Tool
NY-SMARTSTREAM18.10.2017 14:02 | pressemeddelelse
SmartStream and Credit Suisse Expand their Agreement from the Processing of Invoices and Reconciliations to Now Include Listed Derivatives Brokerage Fees
MA-BIOGEN18.10.2017 13:32 | pressemeddelelse
Biogen Confirms Commitment to Tackle Multiple Sclerosis Through Comprehensive Approach
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum